###### Key messages

**What are the new findings?**

1.  This study highlights the impact of glenoid labral lesions in patients with rotator cuff tears on health-related quality-of-life outcomes.

2.  Patients with rotator cuff tear with labral pathologies tend to do worse on outcomes than those without labral pathologies.

**How might it impact clinical practice in the near future?**

1.  This study could help guide clinicians on the importance of labral pathologies in predicting outcomes in patients with rotator cuff tear.

Introduction {#s1}
============

The anatomic configuration of the shoulder joint (glenohumeral joint) is often compared with a golf ball on a tee. The labrum is a fibrocartilaginous ring that attaches to the bony rim of the glenoid fossa,[@R1] doubling the depth of the glenoid fossa to help provide stability.[@R2] The superior labrum attaches to the superior glenoid by loose connective fibres and provides attachment for the long head of the biceps tendon, forming the biceps anchor. The anterior superior labrum is attached to the middle and inferior glenohumeral ligaments, and the inferior labrum is attached firmly to the glenoid by inelastic fibrous tissue.[@R3]

Glenoid labral lesions can often lead to significant discomfort and restriction during daily living activities, as well as various sporting activities.[@R4] The prevalence of these tears can vary between 6% in the general population and 35% in the sporting population.[@R5] The high prevalence of shoulder dysfunction is associated with high societal cost and patient burden. In 2013, a reported 86 690 work-related shoulder injuries and illnesses involving days away from work occurred in the United States.[@R7] In 2005, the treatment measures of shoulder pain accumulated to an estimated annual cost of \$39 billion.[@R8] Zhang *et al* [@R9] reported the highest incidence of repair is in those aged 20--29 years and 40--49 years. In addition, a significant gender difference exists, with men having three times higher incidence of repair.[@R9]

Glenoid labral pathology can be classified based on location and morphology. With respect to location, the labrum can be divided into six areas (superior, posterosuperior, posteroinferior, inferior, anteroinferior and anterosuperior) or alternatively into clock-face 'time zones' (1--12 o'clock) ([figures 1 and 2](#F1 F2){ref-type="fig"}).[@R10] Labral pathology can be classified morphologically as torn, degenerated or blunted. Diagnosis of these pathologies can be

![Labral division: six areas. Figure reproduced from Mohana-Borges *et al* [@R10] with tentative permission of the American Roentgen Ray Society.](bmjsem-2016-000209f01){#F1}

![Labral division: time zones. For both shoulders, 12- to 6-o\'clock position faces anteriorly, and 6- to 12-o\'clock position faces posteriorly. Figure reproduced from Mohana-Borges *et al* [@R10] with tentative permission of the American Roentgen Ray Society.](bmjsem-2016-000209f02){#F2}

optimally performed using magnetic resonance arthrography (MRA). Studies have shown the sensitivity of MRA to be between 82% and 100%, with a specificity of between 71% and 98%.[@R11]

Tears of the superior labrum account for 80%--90% of labral pathology in the stable shoulder.[@R15] These lesions were first described in 1990 by Snyder *et al* [@R16] as superior labrum anterior posterior (SLAP) tears. Originally SLAP tears were classified into four types (I--IV). Subsequently, lesion types V--IX were included in the classification as well.[@R17] The most common mechanisms of injury include chronic, repetitive microtrauma secondary to overhead throwing-type movement or an acute fall onto the outstretched hand.[@R19]

Treatment options for patients presenting with glenoid labral pathology include both surgical and non-surgical interventions. Previous work determined that the population incidence of SLAP repairs in years 2002 and 2009 increased from 3.54 to 10.89 per 100 000.[@R20] Multiple reports document successful outcomes with operative repair of SLAP tears.[@R5] Non-operative repair of SLAP lesions has also been associated with successful outcomes.[@R29] Edwards *et al* reported significant improvements in pain, function and health-related quality of life (HRQoL). The HRQoL measure is increasingly used within orthopaedic research, as clinicians increasingly look beyond strictly functional outcomes to physical, psychological and social factors.[@R30]

Unfortunately, there is not much information on the HRQoL associated with operative interventions of labral pathology. The incentive for this shift from a biomedical model to a psychosocial model has been influenced by research addressing the relationship to HRQoL and successful outcomes within a variety of orthopaedic disciplines, including labral and rotator cuff disease.[@R31] It is the intent of this research to examine the outcomes and HRQoL between operative and non-operative groups in a cohort of patients with labral pathology. The research will also compare patients presenting with labral tears with those presenting with labral degenerations.

Methods {#s2}
=======

Study design {#s2a}
------------

A cohort sample of 123 patients presenting with glenoid labral pathologies (tears or degenerations) was identified retrospectively by sampling consecutive patients from July 2012 to January 2015 from a pragmatic prospective Shoulder Registry cohort.

Inclusion/exclusion criteria {#s2b}
----------------------------

The following were the inclusion criteria: (1) greater than 18 years of age, (2) labral tear of any size and (3) the first tear of the affected shoulder. The following were the exclusion criteria: (1) a labral tear in which complete footprint coverage is not possible (for the surgical group); and (2) history of prior surgery, fracture, dislocation or infection of the affected shoulder.

Data collection {#s2c}
---------------

Study approval was obtained from the University of Michigan Institutional Review Board (no HUM00056320). Participants provided baseline demographic information and completed several previously validated paper-based outcome measures. Data collected included the pain Visual Analogue Scale (VAS), the Veterans RAND 12-Item Health Survey (VR-12), Western Ontario Rotator Cuff Index (WORC), American Shoulder and Elbow Surgeons (ASES) instrument, Scapular Assistance Test (SAT), Shoulder Activity Level (SAL), and Single Assessment Numeric Evaluation (SANE). Participants were tracked for operative versus non-operative intervention and completed the same measures at baseline and at 6-month, 12-month and 2-year follow-ups (excluding SAL, which was collected at baseline only).

Measures {#s2d}
--------

The primary outcome measure used was the pain VAS, which is self-completed by the respondent. The respondents are asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance (millimetre) on the 10 cm line between the 'no pain' anchor and the patient's mark, providing a range of scores from 0 to 100.[@R34] A higher score indicates greater pain intensity.

The VR-12 Health Survey was derived from the RAND 36-item Short-Form Health Survey (SF-36).[@R35] The VR-12 is a self-administered health survey used to measure HRQoL and estimate disease burden. This instrument comprises 12 items corresponding to eight principal physical and mental health domains. These domains include general health perceptions, physical functioning, role limitations due to physical and emotional problems, bodily pain, energy-fatigue, social functioning, and mental health. The 12 items are then summarised into two scores, a 'physical component summary' (PCS) score and a 'mental component summary' (MCS) score.

The WORC index is a valid, reliable and responsive HRQoL self-assessment measurement tool for shoulder disease.[@R39] A recently published study determined the WORC to have the highest ratings among all shoulder instruments.[@R41] The items included in the instrument were determined based on a literature review, along with discussions among patients, orthopaedic surgeons, sports and family physicians, and physiotherapists. The WORC includes 21 questions encompassing five domains. The domains include pain and physical symptoms (six questions), sports and recreation (four questions), work function (four questions), social function (four questions) and emotional function (three questions). In addition to these questions, a 100 mm VAS is included. Scores range from 0 to 100, with a higher score indicating worse shoulder function.

The ASES shoulder outcome score was developed in 1994 in the United States by the research committee of the ASES.[@R42] The purpose was to measure shoulder function through a physician-determined and self-assessment questionnaire. The instrument is divided into three domains: pain, instability and activities of daily living. These domains includes several yes/no questions and a VAS. A 4-point ordinal scale rates 10 questions, with a maximum score for the self-assessment portion of 30. This score is converted to a 100-point scale (100 is the best score). The construct validity, internal consistency and reliability have been shown to be good.[@R43]

The SAT instrument is presumed to indirectly measure the function of the scapular rotators.[@R49] In this test, the examiner pushes laterally and upward on the inferior medial border of the scapula to simulate the serratus anterior/lower trapezius force couple as the patient elevates the arm. According to Kibler,[@R50] the SAT is considered positive if the manual assistance diminished or abolished the symptoms of impingement. The subject rates the pain felt while performing the movement with the assistance of the examiner on an 11-point scale. A reduction of two or more points on the 11-point numeric pain rating scale during assisted elevation, compared with elevation without assistance, is considered a positive test. Previous work has shown that a reduction of 2 points on an 11-point numeric pain rating scale represents a clinically important difference.[@R51] This instrument has been shown to provide moderate inter-rater reliability.[@R52]

The SAL instrument generates a score based on the patient's greatest level of activity during the previous year. The most recent level of activity may be limited by other factors such as weather, conflicting commitments, or complicating illness or injury.[@R53] The patient's greatest activity level during a 1-year period is likely to be the most accurate.[@R54] A reasonable interpretation of the numeric activity score is high, ≥16 (mean+SD); average, 7--15; and low, ≤6 (mean--SD).

The SANE rating is determined by the patient's written response to the following question: 'How would you rate your shoulder today as a percentage of normal (0% to 100% scale, with 100% being normal)?' SANE correlates well with similar outcome scores; correlation coefficients of 0.46--0.69 have been found for SANE and ASES scores.[@R55]

Statistical analysis {#s2e}
--------------------

A sample-size calculation was performed (n=54, α=0.05, β=0.10, effect size=0.913) using a hypothesised difference in change in pain scores in operative versus non-operative interventions (G\*Power v3.1.9.2). Descriptive and inferential analyses were conducted using SAS v. 9.4. χ^2^ analysis and Student's t-test were used to examine the differences between categorical and continuous variables at baseline and at 2-year follow-up. Analysis of variance was used to test the differences between groups. Data were then stratified based on labral pathology. Methods were repeated for each level of stratification.

Simple linear regression analyses were performed on statistically significant baseline characteristics within each strata of labral pathology. These outcome measures for patients with labral tear included pain VAS and ASES scores at baseline. For labral degeneration patients, models were created using age and ASES scores at baseline. Change in pain VAS from baseline to 2-year follow-up was used as the outcome variable for the models.

Results {#s3}
=======

Participant demographics consisted of 123 patients. Of these, 82 were male and 41 were female ([table 1](#T1){ref-type="table"}). There were 68 participants in the non-operative group and 55 in the operative group. Comparing baseline demographics and clinical characteristics indicated a significant difference in age (p=0.01), with non-operative patients being older. Among baseline scores, there were significant differences in pain VAS (p=0.02) and baseline ASES score (p=0.01), with both baseline scores indicating 'worse' scores for the operative patients. No significant differences were noted between groups for baseline PCS, MCS, WORC, SAT, SANE and SAL scores.

###### 

Demographics, clinical features and baseline outcome scores

                      Operative (n=55)   Non-operative (n=68)                                                               
  ------------------- ------------------ ---------------------- -------------------- --------- -------- ------------------- --------
  Age\*               58.51              9.11                   56.05 to 60.97       63.09     10.06    60.65 to 65.52      0.0100
  Gender†                                                                                                                   0.3694
   Male               39                 70.91                                       43        63.24                        
   Female             16                 29.09                                       25        36.76                        
  Body mass index\*   28.63              5.31                   27.19 to 30.07       28.54     5.78     27.14 to 29.94      0.9272
  Cause of injury†                                                                                                          0.3694
   Known              39                 70.91                                       43        63.24                        
   Unknown            16                 29.09                                       25        36.76                        
  Labral pathology†                                                                                                         0.0813
   Tear               28                 50.91                                       24        35.29                        
   Degeneration       27                 49.09                                       44        64.71                        
  Side of injury†                                                                                                           0.2655
   Right              31                 56.36                                       45        66.18                        
   Left               24                 43.64                                       43        33.82                        
  Symptom duration†                                                                                                         0.4084
   \<1 year           21                 38.18                                       31        45.59                        
   \>1 year           34                 61.82                                       27        54.41                        
  Diabetes†                                                                                                                 0.4529
   Yes                7                  12.73                                       12        17.65                        
   No                 48                 87.27                                       56        82.35                        
  Smoking†                                                                                                                  0.7559
   Yes                4                  7.27                                        4         5.88                         
   No                 51                 92.73                                       64        94.12                        
  Pain VAS\*          54.31              26.26                  46.99 to 61.62       42.57     26.93    35.95 to 49.19      0.0191
  Baseline PCS\*      39.11              9.02                   36.14 to 42.07       40.03     8.66     37.49 to 42.58      0.6308
  Baseline MCS‡       48.50              11.24                  44.81 to 52.19       51.47     10.22    48.47 to 54.47      0.2909
  Baseline ASES\*     50.63              21.30                  44.64 to 56.62       60.73     20.67    55.34 to 66.12      0.0132
  Baseline WORC\*     1184.30            455.20                 1058.80 to 1309.80   1061.90   453.90   947.60 to 1176.20   0.1512
  SAT‡                79.20              26.08                  71.55 to 86.86       70.23     33.10    61.28 to 79.18      0.1726
  SANE‡               30.94              24.04                  24.32 to 37.57       37.34     22.88    31.67 to 43.01      0.0819

\*p values calculated using t-tests.

†p values calculated using Wilcoxon signed-rank tests.

‡p values calculated using chi-square tests.

Continuous data presented as mean, SD. Categorical data presented as n (%).

ASES, American Shoulder and Elbow Surgeons; MCS, mental component summary; PCS, physical component summary; SAL, Shoulder Activity Level; SANE, Single Assessment Numeric Evaluation; SAT, Scapular Assistance Test; VAS, Visual Analogue Scale; WORC, Western Ontario Rotator Cuff Index.

Paired sample t-tests within the operative group indicate significant improvements between baseline and 2-year scores for pain VAS (mean difference (MD)=−38.51, p\<0.01), PCS (MD=8.75, p\<0.01), MCS (MD=3.49, p=0.05), ASES (MD=35.53, p\<0.01), WORC (MD=−826.2, p\<0.01), SAT (MD=9.82, p\<0.01) and SANE (MD=53.08, p\<0.01) ([table 2](#T2){ref-type="table"}). Paired sample t-tests within the non-operative group indicate significant improvements between baseline and 2-year scores for PCS (MD=3.53, p=0.02), ASES (MD=10.63, p\<0.01), WORC (MD=−295.3, p\<0.01), SAT (MD=7.95, p=0.02) and SANE (MD=21.89, p\<0.01). When comparing the difference of the 2-year means of outcome measures between groups, only MCS (p=0.81) and SAT (p=0.1) did not display a significant improvement.

###### 

Mean differences of outcome measures from baseline to 2-year follow-up within and between operative and non-operative groups

              Operative (n=55)   Non-operative (n=68)                                                                                                                                                                                    
  ----------- ------------------ ---------------------- ------------- ----------------- -------------------- ------------------------ ---- --------------- ------------- ----------------- -------------------- ------------------------ ------------------------
              n                  Baseline mean          2-year mean   Mean difference   95% CI               Within group p value\*   n    Baseline mean   2-year mean   Mean difference   95% CIs              Within group p value\*   Between group p value†
  Pain VAS‡   36                 47.43                  8.92          −38.51            −29.89 to −47.14     \<0.0010                 48   42.74           33.48         −9.26             0.61 to −19.13       0.0652                   \<0.0001
  PCS‡        29                 41.31                  50.06         8.75              11.56 to 5.94        \<0.0001                 41   40.00           43.52         3.53              6.59 to 0.47         0.0248                   0.0002
  MCS§        29                 51.02                  54.51         3.49              7.77 to −0.79        0.0511                   41   51.06           53.24         2.18              4.74 to −0.39        0.0879                   0.8108
  ASES‡       32                 54.72                  90.25         35.53             43.43 to 27.63       \<0.0001                 41   61.7317         72.37         10.63             16.86 to 4.41        0.0013                   \<0.0001
  WORC‡       37                 1112.16                285.95        −826.20           −678.00 to −974.40   \<0.0001                 46   1006.52         711.22        −295.30           −121.80 to −468.80   0.0013                   \<0.0001
  SAT§        34                 79.68                  89.50         9.82              19.35 to 0.29        0.0034                   38   72.61           80.55         7.95              16.32 to −0.43       0.0205                   0.0981
  SANE§       36                 29.81                  82.89         53.08             63.05 to 43.11       \<0.0001                 48   36.03           57.92         21.89             30.89 to 12.88       \<0.0001                 \<0.0001

\*p values for mean difference from baseline to 2-year mean.

†p values for difference between 2-year operative mean and 2-year non-operative mean.

‡p values calculated using t-tests.

§p values calculated using Wilcoxon signed-rank tests.

ASES, American Shoulder and Elbow Surgeons; MCS, mental component summary; PCS, physical component summary; SANE, Single Assessment Numeric Evaluation; SAT, Scapular Assistance Test; VAS, Visual Analogue Scale; WORC, Western Ontario Rotator Cuff Index.

Labral tear patient demographics consisted of 52 patients. Of these, 36 were male and 16 were female ([table 3](#T3){ref-type="table"}). There were 28 patients in the operative group and 24 in the non-

###### 

Labral tear demographics, clinical features and baseline outcome scores

                      Operative (n=28)   Non-operative (n=24)                                                                
  ------------------- ------------------ ---------------------- -------------------- ---------- -------- ------------------- ---------
                      Mean (n)           SD (%)                 95% CI               Mean (n)   SD (%)   95% CI              p Value
  Age\*               57.89              9.27                   54.30 to 61.49       59.33      11.74    54.38 to 64.29      0.6232
  Gender†                                                                                                                    0.3303
   Male               21                 75.00                                       15         53.57                        
   Female             7                  25.00                                       9          46.43                        
  Body mass index\*   27.24              5.46                   25.12 to 29.36       27.80      6.32     25.13 to 30.47      0.7310
  Cause of injury†                                                                                                           0.6250
   Known              21                 75.00                                       18         64.29                        
   Unknown            7                  25.00                                       6          35.71                        
  Side of injury†                                                                                                            0.5479
   Right              14                 50.00                                       14         58.33                        
   Left               14                 50.00                                       10         41.67                        
  Symptom duration†                                                                                                          0.6856
   \<1 year           9                  32.14                                       9          37.50                        
   \>1 year           19                 67.86                                       15         62.50                        
  Diabetes†                                                                                                                  0.1103
   Yes                1                  3.57                                        4          14.29                        
   No                 27                 96.43                                       20         85.71                        
  Smoking†                                                                                                                   0.8408
   Yes                3                  10.71                                       3          10.71                        
   No                 25                 89.29                                       25         89.29                        
  Pain VAS\*          57.36              27.71                  45.92 to 68.80       40.58      27.29    29.06 to 52.11      0.0381
  Baseline PCS\*      36.83              7.89                   33.03 to 40.64       37.90      10.45    32.70 to 43.10      0.7271
  Baseline MCS‡       48.57              11.85                  42.86 to 54.29       51.38      10.01    46.41 to 56.36      0.5136
  Baseline ASES\*     51.27              22.33                  42.25 to 60.29       63.90      20.37    54.63 to 73.18      0.0510
  Baseline WORC\*     1209.60            444.80                 1033.70 to 1385.60   1042.90    476.80   831.50 to 1254.30   0.2126
  SAT‡                79.45              26.12                  67.87 to 91.04       62.81      38.03    45.50 to 80.12      0.2431
  SANE‡               27.94              22.10                  19.01 to 36.87       39.50      24.71    29.07 to 49.93      0.0754
  SAL\*               11.21              8.60                   8.61 to 13.81        9.76       4.51     7.45 to 12.08       0.3925

*\**p values calculated using t-tests.

†p values calculated using χ^2^ tests.

‡p values calculated using Wilcoxon signed-rank tests.

Continuous data presented as mean, SD. Categorical data presented as n (%).

ASES, American Shoulder and Elbow Surgeons; MCS, mental component summary; PCS, physical component summary; SAL, Shoulder Activity Level; SANE, Single Assessment Numeric Evaluation; SAT, Scapular Assistance Test; VAS, Visual Analogue Scale; WORC, Western Ontario Rotator Cuff Index.

operative group. Comparing baseline demographics and clinical characteristics revealed no significant differences. Among baseline outcome scores, there were differences in pain VAS (p=0.04) and ASES scores (p=0.05). Both baseline outcome scores indicated 'worse' for the operative patients. No significant differences were noted between groups for baseline PCS, MCS, WORC, SAT, SANE and SAL scores.

Paired sample t-tests for patients with labral tear within the operative group indicate significant improvements between baseline and 2-year follow-up scores for pain VAS (MD=−43.08, p\<0.01), PCS (MD=10.81, p\<0.01), ASES (MD=35.39, p\<0.01), WORC (MD=−891.74, p\<0.01), SAT (MD=11.41, p=0.03) and SANE (MD=55.08, p\<0.01) ([table 4](#T4){ref-type="table"}). Paired sample t-tests within the non-operative group for patients with labral tear indicate significant improvements between baseline and 2-year follow-up scores for the PCS (MD=6.89, p=0.02), ASES (MD=7.38, p\<0.01), WORC (MD=−277.76, p=0.04) and SANE (MD=15.55, p=0.03). When comparing the difference of the 2-year means of outcome measures between groups, only PCS (p=0.07), MCS (p=0.77) and SAT (p=0.07) did not display a significant improvement.

###### 

Labral tear mean differences of outcome measures from baseline to 2-year follow-up within and between operative and non-operative groups

  Labral tear (n=52)                                                                                                                                                                                                                                
  -------------------- ------------------ ---------------------- ------------- ------------------ --------------------- ------------------------ ---- --------------- ------------- ------------------ ------------------- ------------------------ ------------------------
                       Operative (n=28)   Non-operative (n=24)                                                                                                                                                                                      
                       n                  Baseline mean          2-year mean   Mean differ-ence   95% CI                Within group p value\*   n    Baseline mean   2-year mean   Mean differ-ence   95% CIs             Within group p value\*   Between group p value†
  Pain VAS‡            18                 50.81                  7.72          −43.08             −31.71 to −54.45      \<0.0001                 20   41.10           33.10         −8.00              4.89 to −20.89      0.2094                   0.0014
  PCS‡                 15                 38.30                  49.10         10.81              14.16 to 7.45         \<0.0001                 17   37.31           44.20         6.89               12.37 to 1.42       0.0167                   0.0726
  MCS§                 15                 50.82                  54.01         3.19               10.02 to −3.65        0.1876                   17   50.69           52.80         2.11               5.97 to −1.75       0.4586                   0.7659
  ASES‡                18                 57.78                  93.17         35.39              45.24 to 25.54        \<0.0001                 16   61.56           68.94         7.38               14.21 to 0.54       0.0363                   0.0002
  WORC‡                19                 1139.74                248.00        −891.74            −701.00 to −1082.50   \<0.0001                 17   1003.76         726.00        −277.76            −21.81 to −533.70   0.0352                   0.0027
  SAT§                 16                 80.03                  91.44         11.41              23.47 to −0.66        0.0305                   17   66.68           73.94         7.27               20.70 to −6.17      0.2490                   0.0670
  SANE§                18                 28.58                  83.67         55.08              64.43 to 45.73        \<0.0001                 20   39.75           55.30         15.55              27.69 to 3.41       0.0319                   0.0012

*\**p values for mean difference from baseline to 2-year mean.

†p values for difference between 2-year operative mean and 2-year non-operative mean.

‡p values calculated using t-tests.

§p values calculated using Wilcoxon signed-rank tests.

ASES, American Shoulder and Elbow Surgeons; MCS, mental component summary; PCS, physical component summary; SANE, Single Assessment Numeric Evaluation; SAT, Scapular Assistance Test; VAS, Visual Analogue Scale; WORC, Western Ontario Rotator Cuff Index.

Labral degeneration patient demographics consisted of 71 patients. Of these, 46 were male and 25 were female ([table 5](#T5){ref-type="table"}). There were 27 patients in the operative group and 44 in the non-operative group. Comparing

###### 

Labral degeneration demographics, clinical features and baseline outcome scores

  ----------------------------------------------------------------------------------------------------------------------------------
                      Operative (n=27)   Non-operative (n=44)                                                              
  ------------------- ------------------ ---------------------- ------------------- --------- -------- ------------------- ---------
                      Mean/n             SD/%                   95% CI              Mean/n    SD/%     95% CI              p Value

  Age\*               59.15              9.07                   55.56 to 62.73      65.14     8.48     62.56 to 67.72      0.0064

  Gender†                                                                                                                  0.7952

   Male               18                 66.67                                      28        63.64                        \

   Female             9                  33.33                                      16        36.36                        

  Body mass index\*   30.07              4.84                   28.15 to 31.99      28.94     5.50     27.26 to 30.61      0.3815

  Cause of injury†                                                                                                         0.4098

   Known              18                 66.67                                      25        56.82                        

   Unknown            9                  33.33                                      19        43.18                        

  Side of injury†                                                                                                          0.5126

   Right              17                 62.96                                      31        70.45                        

   Left               10                 37.04                                      13        29.55                        

  Symptom duration†                                                                                                        0.6492

   \<1 year           15                 55.56                                      22        50                           

   \>1 year           12                 44.44                                      22        50                           

  Diabetes†                                                                                                                0.6779

   Yes                6                  22.22                                      8         18.18                        

   No                 21                 77.78                                      36        81.82                        

  Smoking†                                                                                                                 0.7235

   Yes                1                  3.70                                       1         2.27                         

   No                 26                 96.30                                      43        97.73                        

  Pain VAS\*          51.48              25.02                  41.58 to 61.38      43.70     27.00    35.29 to 52.11      0.2338

  Baseline PCS\*      41.38              9.70                   36.70 to 46.05      41.36     7.23     38.61 to 44.11      0.9937

  Baseline MCS‡       48.43              10.91                  43.17 to 53.69      51.52     10.53    47.51 to 55.53      0.4231

  Baseline ASES\*     49.96              20.61                  41.45 to 58.47      58.97     20.89    52.11 to 65.84      0.0973

  Baseline WORC\*     1158.00            473.10                 966.90 to 1349.10   1072.10   446.80   931.10 to 1213.10   0.4562

  SAT‡                78.98              26.58                  68.01 to 89.95      74.81     29.32    64.58 to 85.04      0.4518

  SANE‡               33.83              25.86                  23.60 to 44.06      36.07     21.96    29.14 to 43.01      0.5185

  SAL\*               10.69              3.86                   8.63 to 12.74       11.76     5.01     9.48 to 14.04       0.4816
  ----------------------------------------------------------------------------------------------------------------------------------

\*p values calculated using t-tests.

†p values calculated using χ^2^ tests.

‡p values calculated using Wilcoxon signed-rank tests.

Continuous data presented as mean, SD. Categorical data presented as n (%).

ASES, American Shoulder and Elbow Surgeons; MCS, mental component summary; PCS, physical component summary; SAL, Shoulder Activity Level; SANE, Single Assessment Numeric Evaluation; SAT, Scapular Assistance Test; VAS, Visual Analogue Scale; WORC, Western Ontario Rotator Cuff Index.

baseline demographics and clinical characteristics indicated a significant difference in age (p=0.01), with non-operative patients being older. No significant differences in outcome measures were noted between groups.

Paired sample t-tests for patients with labral degeneration within the operative group (n=27) indicated significant improvements between baseline and 2-year follow-up scores for pain VAS (MD=−33.94, p\<0.01), PCS (MD=6.55, p=0.01), ASES (MD=35.71, p\<0.01), WORC (MD=−757.06, p\<0.01) and SANE (MD=51.08, p\<0.01) ([table 6](#T6){ref-type="table"}). Paired sample t-tests within the non-operative group (n=44) for patients with labral degeneration indicate significant improvements between baseline and 2-year follow-up scores for ASES (MD=12.72, p=0.01), WORC (MD=−305.59, p=0.02) and SANE (MD=26.41, p\<0.01). When comparing the difference of the 2-year means of outcome measures between the two groups, only MCS (p=0.51) and SAT (p=0.44) did not display a significant improvement.

###### 

Labral degeneration mean differences of outcome measures from baseline to 2-year follow-up within and between operative and non-operative groups

  Labral degeneration (n=71)                                                                                                                                                                                                           
  ---------------------------- ---- --------------- ------------- ------------------ --------------------- ------------------------ ---- --------------- ------------- ------------------ ------------------- ------------------------ ------------------------
                               n    Baseline mean   2-year mean   Mean differ-ence   95% CI                Within group p value\*   n    Baseline mean   2-year mean   Mean differ-ence   95% CIs             Within group p value\*   Between group p value†
  Pain VAS‡                    18   44.06           10.11         −33.94             −20.13 to −47.76      \<0.0001                 28   43.91           33.75         −10.16             4.73 to −25.05      0.1729                   0.0027
  PCS‡                         14   44.54           51.09         6.55               11.30 to 1.79         0.0108                   24   41.90           43.04         1.14               4.68 to −2.39       0.5096                   0.0012
  MCS§                         14   51.24           55.06         3.82               9.81 to −2.18         0.2349                   24   51.33           53.55         2.22               5.90 to −1.46       0.1394                   0.5065
  ASES‡                        14   50.79           86.50         35.71              50.22 to 21.21        0.0001                   25   61.84           74.56         12.72              22.25 to 3.19       0.0110                   0.0523
  WORC‡                        18   1083.06         326.00        −757.06            −512.10 to −1002.10   \<0.0001                 29   1008.14         702.55        −305.59            −63.00 to −548.20   0.0154                   0.0102
  SAT§                         18   79.36           87.78         8.42               24.08 to −7.24        0.0798                   21   77.40           85.90         8.50               20.14 to −3.14      0.0650                   0.4425
  SANE§                        18   31.03           82.11         51.08              69.86 to 32.31        0.0002                   28   33.38           59.79         26.41              39.56 to 13.26      0.0001                   0.0186

\*p values for mean difference from baseline to 2-year mean.

†p values for difference between 2-year operative mean and 2-year non-operative mean.

‡p values calculated using t-tests.

§p values calculated using Wilcoxon signed-rank tests.

ASES, American Shoulder and Elbow Surgeons; MCS, mental component summary; PCS, physical component summary; SANE, Single Assessment Numeric Evaluation; SAT, Scapular Assistance Test; VAS, Visual Analogue Scale; WORC, Western Ontario Rotator Cuff Index.

In our linear regression analyses for patients with labral tear using change in pain VAS score from baseline to 2-year follow-up as the response variable, we found baseline pain VAS (β=−0.718, p\<0.01) and ASES scores (β=0.597, p=0.03) were significant predictor variables. Also, in the linear regression analyses for labral degeneration, we found baseline ASES scores (β=0.663, p=0.02) to be significant predictors of change in pain.

Discussion {#s4}
==========

Many published studies have demonstrated good to excellent outcomes of repairs of labral pathology. However, orthopaedic research is increasingly assessing results using HRQoL measures. In this particular patient population, the two groups were fairly homogenous regarding variables related to the injury, such as type of labral pathology, cause of injury, side of injury and symptom duration. However, the operative group was younger and had significantly worse baseline scores for pain VAS and ASES. These differences could be attributed to the guidelines and recommendations provided to physicians for determining whether a patient should elect operative or non-operative treatment. The patient who elected operative intervention experienced significantly improved long-term HRQoL outcomes and function scores. This trend held true after stratification by labral pathology, as operative patients consistently reported more favourable outcome scores after the 2-year follow-up period.

In this patient population, pain VAS was significantly higher in the operative group at baseline. However, there was evidence to support the efficacy of surgical intervention as these patients electing operative treatment displayed significant improvements from baseline to 2-year follow-up across all outcome measures. While the non-operative group also reported significant improvements in outcome measures, the operative group exhibited larger MDs from baseline to follow-up, as well as higher scores associated with better outcomes. Additionally, the reported raw 2-year follow-up scores were significantly higher/improved when compared with the non-operative group except for MCS and SAT.

Although numerous studies explicitly examine the functional outcomes following labrum repair,[@R5] few studies look at the relationship between labral pathology and quality of life. The HRQoL outcomes for participants in the present study support previous research that has been conducted with non-operative patients. While the present study used the VR-12 as the HRQoL measure, studies that have used different HRQoL measures have reported similar results. Edwards *et al* [@R29] found in non-operative patients that the SF-36, ASES and VAS scores all improved at final follow-up.

VR-12 (MCS and PCS) scores were not significantly different at baseline between operative and non-operative groups. Despite observing an increased MCS score in both operative and non-operative groups, there was no statistical difference between 2-year MCS scores of either treatment group. Throughout this study, MCS consistently did not display significant improvements over time. This phenomenon is not fully understood, but can possibly be attributed to the nature of a repaired labrum. Previous research involving overhead athletes receiving non-operative treatments of SLAP tears found return to sport difficult to achieve, despite improvement in pain scores[@R29]: 'Although 71% of patients returned to the same or better levels of participation, only 10 of the 15 overhead athletes (67%) returned to their overhead sport at the same or higher level'.[@R29] Additionally, Cohen *et al* [@R21] found that only 14 of 29 patients (48%) in their series could return to pre-participation levels after SLAP repair, and only 71% of patients were satisfied. This may suggest that patients in our population experienced less pain and higher PCS scores, but did not report increased MCS scores due to disappointing results when returning to sport or work.

Stratifying by labral pathology allowed a deeper look into the relationship between treatment and HRQoL. Among patients with labral tears, the two groups were fairly homogenous except for the operative group presenting significantly worse baseline scores for pain VAS and ASES. As previously mentioned, this difference is likely the result of physician guidelines and recommendations for patients presenting with higher levels of pain. In this population, only the operative group reported a significant improvement in pain VAS scores. Both groups displayed significant improvement in PCS scores from baseline to 2-year follow-up, with operative patients reporting a nearly statistically greater improvement in PCS scores. The efficacy of operative treatment of labral tears has been shown again, as operative patients displayed larger improvement in pain VAS, ASES, WORC and SANE scores when compared with non-operative patients.

Patients presenting with labral degenerations reported improvements in outcome scores. However, it is important to note non-significant improvements in pain VAS and PCS scores in patients receiving non-operative treatment. Operative patients reported significant improvements in these scores, further supporting surgical treatment of labral pathologies. While it may seem intuitive for a physician to treat a less severe lesion with a conservative approach, this stratified non-operative group displayed the smallest MD in scores from baseline to 2-year follow-up.

Study limitations include single-centre patient information, as well as smaller sample sizes after stratification. Additionally, the patient population was derived from patients presenting with rotator cuff pathology. Despite controlling for this variable, it may prove useful to investigate the effects of treatment on patients presenting specifically with labral pathology. Future research may include additional long-term trials evaluating HRQoL in patients choosing operative and non-operative treatment modalities.

The present study provides important information on expected outcomes in patients who receive operative or non-operative treatment for labral pathologies, and may help guide decisions on when to consider intervention types based on these criteria. Operative groups in this cohort consistently exhibited larger MDs for all outcome measures, and higher scores associated with better outcomes. This study demonstrates that patients who received operative treatment of labral pathology (either a tear or degeneration) significantly improved HRQoL and outcome scores after 2 years when compared with non-operative treatment.
